Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in Patients with Previous Prostate Radiotherapy

Table 2

Pathological and clinical outcomes of radical cystectomy following BCG failure.

	Group 1 (RT)	Group 2 (RP)	Group 3 (no PC/RT)	P-value
Pathological stage
pT0	2 (17)	1 (17)	2 (6)	0.36
pTis	1 (8)	1 (17)	9 (26)
pTa	0	0	3 (9)
pT1	2 (17)	2 (33)	14 (40)
pT2	3 (25)	0	4 (11)
pT3	3 (25)	2 (33)	2 (6)
pT4	1 (8)	0	1 (3)
Any CIS in final pathologic specimen	3 (25)	2 (33)	30 (86)	<0.001
Upstaged (≥T2 or N+)	8 (58)	2 (33)	7 (20)	0.01
Node-positive	2 (33)	0	1 (3)	0.17
Positive Margin	2 (17)	0	3 (9)	0.43
No. of pts with recurrence	6 (58)	0	10 (29)	0.09
Local (urethra, pelvis)	5 (42)	0	4 (11)	0.028
Pelvic soft tissue	3	0	2
Urethra	2	0	2
Urothelial (ureter/upper tract)	2 (17)	0	8 (23)	0.65
Distant	0	0	1 (3)	0.55

Numbers represent mean ± SD or no. (%) as appropriate.